Takeda Pharmaceutica (TKPHF) 48.1000 $TKPHF Obesity

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Takeda Pharmaceutica (TKPHF) 48.1000 $TKPHF

Obesity Drugs: Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Tue Jun 09, 10:06AM CDT
Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million people, are believed to be obese, putting them at increased risk of certain forms of cancer, cardiovascular disease, and type 2 diabetes, among many...
OREX: 4.70 (+0.04), ARNA: 4.29 (+0.04)

Asco - A Sirius Lead For Daratumumab
EP Vantage - at Seeking Alpha - Mon Jun 01, 12:16PM CDT
G enmab ( OTCPK:GMXAY , OTC:GNMSF investors celebrated earlier this month when Johnson & Johnson (NYSE: JNJ ) said it would file its partnered multiple myeloma project daratumumab this year based on the phase II Sirius study. Recently...
JNJ: 99.53 (+1.13), CELG: 118.84 (+1.97)

Synergy: This Popular Biotech Is Approaching A Major Clinical Event, Here's How To Trade It
Lowenthal Capital Partners - at Seeking Alpha - Sat May 30, 12:05PM CDT

SGYP: 9.13 (+0.49), IRWD: 11.44 (-0.06)

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Brian Orelli, The Motley Fool - Motley Fool - Sat May 16, 10:04AM CDT
Orexigen Therapeutics has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals and VIVUS weren't able to do: keep its share price above where it was when its weight-loss drug was approved in September. ...
OREX: 4.70 (+0.04), VVUS: 2.15 (+0.02), ARNA: 4.29 (+0.04)

Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 180.86 (+0.85), VRTX: 122.95 (+2.06), OVAS: 27.28 (+0.82), MYL: 71.22 (+0.87), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), ALR: 52.77 (+0.40), ONTY: 3.66 (+0.04), CELG: 118.84 (+1.97), PVCT: 0.51 (+0.01), JNJ: 99.53 (+1.13), OREX: 4.70 (+0.04), FCSC: 5.40 (+0.27), NVIV: 14.01 (-1.01), GILD: 113.74 (+0.38), GWPH: 125.86 (+5.39), CTSO: 6.20 (+0.40), ACHN: 8.68 (+0.14), RMD: 57.05 (+0.28), SNY: 51.49 (+2.71), PBYI: 106.25 (-2.12)

Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT

PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), LLY: 88.29 (+0.81), SNY: 51.49 (+2.71)

How Not To Handle Your Clinical Data
Derek Lowe - Seeking Alpha - Wed May 13, 11:59AM CDT
We turn now to Orexigen (NASDAQ: OREX ), one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug ( Contrave , a sustained release formulation...
OREX: 4.70 (+0.04)

Takeda - Orexigen partnership on the rocks after CV outcomes study halted
Seeking Alpha - at Seeking Alpha - Wed May 13, 6:25AM CDT

OREX: 4.70 (+0.04)

First patient dosed in Takeda's Phase 3 study of proteasome inhibitor in myeloma
Seeking Alpha - at Seeking Alpha - Tue May 12, 6:31AM CDT


Infinity Pharmaceuticals: Analyzing The Impact Of Repurchasing Takeda's Royalty Agreement
Jonathan Liu - at Seeking Alpha - Mon Apr 13, 7:50PM CDT

INFI: 10.19 (+0.23), ABBV: 69.23 (+1.26)

Takeda Pharma offers $2.2B to settle Actos cases
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:31AM CDT

LLY: 88.29 (+0.81)

Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 10:30AM CDT

ABBV: 69.23 (+1.26), INFI: 10.19 (+0.23)

Why ImmunoGen Inc. is Soaring Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 23, 2:25PM CDT
Although we don't believe in   timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. ImmunoGen, What's happening: Shares in ...
IMGN: 14.44 (+0.25), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81)

Takeda licenses ImmunoGen's ADC technology to develop cancer therapeutics
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 6:47AM CDT

IMGN: 14.44 (+0.25)

Orexigen torpedoes shorts on news of Contrave's heart safety benefit
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 12:03PM CST

OREX: 4.70 (+0.04), VVUS: 2.15 (+0.02), ARNA: 4.29 (+0.04)

Amgen's Kyprolis beats Takeda's Velcade in head-to-head study
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 10:53PM CST

AMGN: 154.10 (+2.79)

Heptares Takes Sosei Out Of Its Comfort Zone
EP Vantage - Seeking Alpha - Mon Feb 23, 2:37PM CST
It makes perfect sense for a small Japanese company to harbour expansion plans, but the private UK neuroscience player Heptares Therapeutics makes an unusual bedfellow for Sosei ( OTC:SOLTF ) , a group with a predominantly respiratory focus....
AZN: 66.45 (+1.90), NVS: 103.22 (+3.20)

Interim results positive for Takeda blood cancer med
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:17AM CST


Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST

SCMP: 18.15 (+0.87)

AMAG and Takeda part ways on ferumoxytol
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 7:31AM CST

AMAG: 71.72 (+2.23)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lawsuit Highlights Inaction in School Bus Tragedy

Updated Category News Views 3

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Updated Category News Views 6

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness

Updated Category News Views 6

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence

Updated Category News Views 3

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Continue Reading
Black Culture Icon: Plastic-Covered Couch Takes Stage

Updated Category News Views 3

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Continue Reading
SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Updated Category News Views 3

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Continue Reading
Class Action Alerts: M&A Under Scrutiny

Updated Category News Views 4

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Continue Reading
ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

Updated Category News Views 5

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris

Updated Category News Views 5

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Continue Reading
Blokees Unveils 90+ New Wonders at Shanghai Fest

Updated Category News Views 3

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring PBK Miner: Pioneering Sustainable Cloud Mining Solutions

Updated Category News Views 190

Discover PBK Miner’s Innovative Approach to Cloud Mining PBK Miner has emerged as a frontrunner in revolutionizing the cryptocurrency mining arena through its unique cloud mining contracts. This UK-based company has designed an innovative platform that enables users to effortlessly increase their income by accumulating cryptocurrency, making it easier than ever to build...

Continue Reading
Tesla Delivery Challenges Highlight Growing Market Competition

Updated Category News Views 439

Tesla's First Annual Delivery Decline Raises Industry Concerns Tesla (NASDAQ: TSLA), the well-known electric vehicle manufacturer, has faced its first-ever annual decline in vehicle deliveries. In the recent period, the company delivered 1.79 million vehicles, slightly lower than the 1.81 million units delivered the previous year. This downturn is unexpected for a brand...

Continue Reading
Therrel Baisden LLP: Celebrating a Century of Legal Excellence

Updated Category News Views 235

Therrel Baisden LLP Marks a Remarkable 100-Year Journey Therrel Baisden LLP, one of Florida’s esteemed boutique estate and trust law firms, is joyously commemorating its centenary. With a rich history of unmatched legal services, the firm has successfully catered to a diverse clientele, both domestically and internationally. A Legacy of Legal Excellence At the heart of...

Continue Reading
Nature's Path Elevates Leadership to Drive Growth Strategy

Updated Category News Views 153

Nature's Path Elevates Leadership for U.S. Growth Nature's Path Organic Foods, the prominent name in organic breakfast and snack foods in North America, has made a significant move by appointing Laura S. Chamberlain as their new Chief Customer Officer (CCO). This newly created role is set to enhance the company's commitment to growth within the U.S. market while nurturing...

Continue Reading
Iovance Biotherapeutics Set for Key Earnings Announcement

Updated Category News Views 232

Iovance Biotherapeutics Set for Key Earnings Announcement Iovance Biotherapeutics (NASDAQ: IOVA) is gearing up for its upcoming quarterly earnings report, and investors are keenly interested in what it has to offer. As anticipated, this announcement is set to unveil critical financial insights that could influence the company's future trajectory. Understanding Earnings...

Continue Reading